{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:09:19Z","timestamp":1793236159799,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007525","name":"Universit\u00e9 de Rennes 1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007525","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.intimp.2023.109723","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T10:16:29Z","timestamp":1674468989000},"page":"109723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis"],"prefix":"10.1016","volume":"116","author":[{"given":"Nessrine","family":"Bellamri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lelong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Joannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Le Tallec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Jouneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Vernhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lescoat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8606-4755","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Lecureur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2023.109723_b0005","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"Perelas","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.109723_b0010","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/1346-8138.14153","article-title":"Systemic sclerosis","volume":"45","author":"Asano","year":"2018","journal-title":"J. Dermatol. f\u00e9vr"},{"key":"10.1016\/j.intimp.2023.109723_b0015","article-title":"The immunopathogenesis of fibrosis in systemic sclerosis","volume":"12","author":"Brown","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2023.109723_b0020","doi-asserted-by":"crossref","unstructured":"A. Lescoat, V. Lecureur, J. Varga, Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications, 33 (6) (2021) 8.","DOI":"10.1097\/BOR.0000000000000835"},{"issue":"1","key":"10.1016\/j.intimp.2023.109723_b0025","doi-asserted-by":"crossref","first-page":"e1004005","DOI":"10.1371\/journal.pcbi.1004005","article-title":"Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms","volume":"11","author":"Mahoney","year":"2015","journal-title":"PLoS Comput. Biol. janv"},{"issue":"1","key":"10.1016\/j.intimp.2023.109723_b0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13073-017-0417-1","article-title":"A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis","volume":"9","author":"Taroni","year":"2017","journal-title":"Genome Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.109723_b0035","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jid.2018.01.006","article-title":"Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin","volume":"138","author":"Hinchcliff","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"11","key":"10.1016\/j.intimp.2023.109723_b0040","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis","volume":"76","author":"Huang","year":"2017","journal-title":"Ann. Rheumatic Diseases."},{"issue":"1","key":"10.1016\/j.intimp.2023.109723_b0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear Antibodies in Systemic Sclerosis: an Update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin. Rev. Allerg. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2023.109723_b0050","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/BOR.0000000000000834","article-title":"Insights into origins and specificities of autoantibodies in systemic sclerosis","volume":"33","author":"Tiniakou","year":"2021","journal-title":"Curr. Opin. Rheumatol."},{"issue":"12","key":"10.1016\/j.intimp.2023.109723_b0055","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/intimm\/dxy055","article-title":"Efferocytosis and autoimmune disease","volume":"30","author":"Kawano","year":"2018","journal-title":"Int. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109723_b0060","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imcb.12217","article-title":"Efferocytosis capacities of blood monocyte-derived macrophages in systemic sclerosis","volume":"97","author":"Ballerie","year":"2019","journal-title":"Immunol. Cell Biol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109723_b0065","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1172\/JCI131700","article-title":"Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis","volume":"130","author":"Maehara","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2023.109723_b0070","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/rheumatology\/kei244","article-title":"Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients","volume":"45","author":"Tan","year":"2006","journal-title":"Rheumatology."},{"issue":"8","key":"10.1016\/j.intimp.2023.109723_b0075","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2023.109723_b0080","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1002\/art.39289","article-title":"Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis","volume":"67","author":"Assassi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2023.109723_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2018.12.018","article-title":"Type I interferon dysregulation in Systemic Sclerosis","volume":"132","author":"Skaug","year":"2020","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.intimp.2023.109723_b0090","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/art.27224","article-title":"Systemic sclerosis and lupus: Points in an interferon-mediated continuum","volume":"62","author":"Assassi","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2023.109723_b0095","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/art.37742","article-title":"Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2023.109723_b0100","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of Interferon- and Transforming Growth Factor \u03b2\u2013Regulated Genes and Macrophage Activation With Systemic Sclerosis-Related Progressive Lung Fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109723_b0105","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12016-020-08798-2","article-title":"Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases","volume":"59","author":"Jiang","year":"2020","journal-title":"Clin. Rev. Allerg. Immunol."},{"key":"10.1016\/j.intimp.2023.109723_b0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.imlet.2017.10.011","article-title":"Targeting interferons as a strategy for systemic sclerosis treatment","volume":"195","author":"Ciechomska","year":"2018","journal-title":"Immunol. Lett."},{"issue":"10","key":"10.1016\/j.intimp.2023.109723_b0115","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/jid.2015.188","article-title":"Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis","volume":"135","author":"Guo","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"Supplement_1","key":"10.1016\/j.intimp.2023.109723_b0120","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: from basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.intimp.2023.109723_b0125","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41409-019-0731-x","article-title":"Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study","volume":"55","author":"Escamilla G\u00f3mez","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.intimp.2023.109723_b0130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.intimp.2017.11.032","article-title":"Repression of interferon \u03b2-regulated cytokines by the JAK1\/2 inhibitor ruxolitinib in inflammatory human macrophages","volume":"54","author":"Febvre-James","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.109723_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114103","article-title":"Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease","volume":"178","author":"Lescoat","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2023.109723_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115972","article-title":"Arsenic trioxide inhibits the functions of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis","volume":"441","author":"Joannes","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109723_b0145","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.intimp.2023.109723_b0150","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","article-title":"Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects","volume":"277","author":"World Medical Association Declaration of Helsinki","year":"1997","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.intimp.2023.109723_b0155","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12185-013-1393-x","article-title":"A phase I\/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia","volume":"98","author":"Ogawa","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"4","key":"10.1016\/j.intimp.2023.109723_b0165","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jcp.41.4.467","article-title":"Simple method of estimating severity of pulmonary fibrosis on a numerical scale","volume":"41","author":"Ashcroft","year":"1988","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.intimp.2023.109723_b0170","unstructured":"Y. Zhang, R. Liang, C.W. Chen, T. Mallano, C. Dees, A. Distler, et al., JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment, 9."},{"issue":"11","key":"10.1016\/j.intimp.2023.109723_b0175","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00403-005-0550-3","article-title":"Increased expression of p53 and p21 (Waf1\/Cip1) in the lesional skin of bleomycin-induced scleroderma","volume":"296","author":"Yamamoto","year":"2005","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.intimp.2023.109723_b0180","doi-asserted-by":"crossref","first-page":"134","DOI":"10.55563\/clinexprheumatol\/g5mej7","article-title":"The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease","volume":"39 Suppl 131(4)","author":"Wollin","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2023.109723_b0185","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00403-006-0712-y","article-title":"Fas- and FasL-deficient mice are resistant to the induction of bleomycin-induced scleroderma","volume":"298","author":"Yamamoto","year":"2007","journal-title":"Arch. Dermatol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2023.109723_b0190","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","article-title":"Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2023.109723_b0195","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12931-018-0891-z","article-title":"A circulating cell population showing both M1 and M2 monocyte\/macrophage surface markers characterizes systemic sclerosis patients with lung involvement","volume":"19","author":"Trombetta","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.intimp.2023.109723_b0200","doi-asserted-by":"crossref","unstructured":"B. Skaug, Type I interferon dysregulation in Systemic Sclerosis. (2020) 7.","DOI":"10.1016\/j.cyto.2018.12.018"},{"issue":"3","key":"10.1016\/j.intimp.2023.109723_b0205","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1096\/fj.08-121228","article-title":"Macrophage phagocytosis of apoptotic neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-inflammatory agents: key role for TNF-\u03b1","volume":"23","author":"Michlewska","year":"2009","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.intimp.2023.109723_b0210","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/art.22382","article-title":"A macrophage marker, siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll-like receptor agonists","volume":"56","author":"York","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.intimp.2023.109723_b0215","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H","article-title":"Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus","volume":"41","author":"Herrmann","year":"1998","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.intimp.2023.109723_b0220","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial","volume":"205","author":"Khanna","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.109723_b0225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12931-018-0728-9","article-title":"The JAK2 pathway is activated in idiopathic pulmonary fibrosis","volume":"19","author":"Milara","year":"2018","journal-title":"Respir. Res."},{"issue":"26","key":"10.1016\/j.intimp.2023.109723_b0230","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.intimp.2023.109723_b0235","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.3390\/ijms22126211","article-title":"Role of JAK\/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms","volume":"22","author":"Montero","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2023.109723_b0240","doi-asserted-by":"crossref","unstructured":"M. Wu, B. Skaug, X. Bi, T. Mills, G. Salazar, X. Zhou, et al., Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis, (2020) 20.","DOI":"10.1136\/annrheumdis-2019-215208"},{"issue":"9","key":"10.1016\/j.intimp.2023.109723_b0245","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis","volume":"64","author":"Dees","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2023.109723_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.595811","article-title":"Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"12","author":"Valenzi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.109723_b0160","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fimmu.2020.00219","article-title":"Crystalline Silica Impairs Efferocytosis Abilities of Human and Mouse Macrophages: Implication for Silica-Associated Systemic Sclerosis","volume":"11","author":"Lescoat","year":"2020","journal-title":"Front. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923000462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923000462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T12:07:58Z","timestamp":1719230878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923000462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":50,"alternative-id":["S1567576923000462"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109723","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109723"}}